The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.
 
Ji Son
No Relationships to Disclose
 
Emily Hinchcliff
Speakers' Bureau - Abbvie
 
Shuqi Wang
No Relationships to Disclose
 
Amir Jazaeri
Stock and Other Ownership Interests - Avenge Bio; Greenfire Bio
Honoraria - Premier Research
Consulting or Advisory Role - Gerson Lehrman Group; Guidepoint Global; Iovance Biotherapeutics; Macrogenics; Sentinel Bio; Theolytics
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); GlaxoSmithKline (Inst); immatics (Inst); Imunon (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Macrogenics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Stryker
 
Anil Sood
Employment - Amgen (I)
Consulting or Advisory Role - Iylon; Onxeo
Patents, Royalties, Other Intellectual Property - EGFL6 antibody royalty payment; SiRNA delivery (patents on DOPC, rHDL)
Other Relationship - Advenchen Laboratories; Mural Oncology
(OPTIONAL) Uncompensated Relationships - Elsevier
 
Bryan Fellman
No Relationships to Disclose
 
Ying Yuan
Consulting or Advisory Role - Abbvie; Amgen; Ascendis Pharma; Astellas Pharma; Bexion; Bristol-Myers Squibb/Celgene/Juno; Century Therapeutics; Century Therapeutics; GT Medical Technologies; Merck; NeoImmuneTech; NGM Biopharmaceuticals; Ono Pharmaceutical; Repare Therapeutics; Schrodinger; SERVIER; Umoja Biopharma; Vertex
 
Nicole Fleming
Consulting or Advisory Role - GlaxoSmithKline; Immunogen; Pfizer; Tesaro
 
Robert Hillman
No Relationships to Disclose
 
Jeffrey How
Research Funding - MacroGenics; Merck
Travel, Accommodations, Expenses - Gilead Sciences
 
Travis Sims
Research Funding - Bristol Myers Squibb Foundation; Gilead Sciences; NIH (Inst)
 
Joseph Davis
No Relationships to Disclose
 
Nancy Tran
No Relationships to Disclose
 
William Feely
Employment - Mereo BioPharma Group PLC
Stock and Other Ownership Interests - Mereo BioPharma Group PLC
 
Adzoa Ekue
Employment - Mereo BioPharma Group PLC
Stock and Other Ownership Interests - Mereo BioPharma Group PLC
 
Yuwei Zhang
No Relationships to Disclose
 
Sreyashi Basu
No Relationships to Disclose
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Affini-T Therapeutics; Affini-T Therapeutics (I); Akoya Biosciences; Akoya Biosciences (I); Apricity Health; Apricity Health (I); Bectas (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Candel Therapeutics; Candel Therapeutics (I); Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; InterVenn Biosciences (I); JSL Health; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Matrisome; Oncolytics; Osteologic; Osteologic Therpeutics (I); PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Sporos Bio; Time Bioventures; Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Affini-T Therapeutics; Apricity Health; Apricity Health (I); Asher Biotherapeutics; BioAtla; BioAtla (I); C-Reveal Therapeutics; Candel Therapeutics; Candel Therapeutics (I); Carisma Therapeutics; Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Henlius; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I); Xilis
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Shannon Westin
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Clovis Oncology; Curio Science; Daiichi Sankyo; Eisai; EQRX; Genentech; Gerson Lehrman Group; Gilead Sciences; GlaxoSmithKline; Immunocore; Immunogen; Incyte; Lilly; Loxo/Lilly; Medscape; Merck; Mereo BioPharma; Mersana; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; Nuvectis Pharma; OncLive; pharma&; Roche; Seagen; Targeted Oncology; Verastem; Vincerx Pharma; Zentalis; ZielBio
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Jazz Pharmaceuticals (Inst); Loxo/Lilly (Inst); Mereo BioPharma (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Roche/Genentech (Inst); Zentalis (Inst)